Scarica l'app Stockscreener
189.08
2.20%
4.07
Dopo l'orario di chiusura:
190.00
0.92
+0.49%
Precedente Chiudi:
$185.01
Aprire:
$186.71
Volume 24 ore:
832.87K
Relative Volume:
0.83
Capitalizzazione di mercato:
$11.64B
Reddito:
$4.27B
Utile/perdita netta:
$-356.15M
Rapporto P/E:
-31.67
EPS:
-5.9702
Flusso di cassa netto:
$1.19B
1 W Prestazione:
+4.78%
1M Prestazione:
-3.94%
6M Prestazione:
+47.95%
1 anno Prestazione:
+39.80%
Intervallo 1D:
$186.00
$189.40
Intervallo di 1 settimana:
$178.40
$189.40
Portata 52W:
$95.49
$198.00
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
189.08 | 11.39B | 4.27B | -356.15M | 1.19B | -5.9702 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Iniziato | Barclays | Overweight |
| 2025-11-24 | Downgrade | UBS | Buy → Neutral |
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
MassMutual Private Wealth & Trust FSB Sells 7,073 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
A Voice for Advocacy and Awareness in HER2+ Gastroesophageal AdenocarcinomaJazz Pharmaceuticals - Oncodaily
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education - Lelezard
Is Jazz Pharmaceuticals (JAZZ) one of the best cheap biotech stocks to buy now? - MSN
People with sleep disorders to get guidance on sodium, heart risk - Stock Titan
Is the options market predicting a spike in Jazz Pharmaceuticals stock? - MSN
How New Ziihera and JZP898 Data from AACR 2026 Will Impact Jazz Pharmaceuticals (JAZZ) Investors - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) reports $1.2 billion Q4 revenue, beats $1.17B estimate - MSN
Groupama Asset Managment Lowers Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals’ EBITDA Set to Surge 175% in 2026: Here’s What’s Next - TIKR.com
Narcolepsy Therapeutics Market (2025) | Central Nervous System - openPR.com
Why is Jazz Pharmaceuticals plc stock going up2026 Technical Overview & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Piper Sandler Maintains Overweight Rating for JAZZ, Raises Price Target | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $232.00 Price Target at Piper Sandler - MarketBeat
Piper Sandler raises Jazz Pharmaceuticals stock price target on growth outlook - Investing.com UK
Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026 - Yahoo Finance
A Look At Jazz Pharmaceuticals (JAZZ) Valuation As New Oncology Data Heads To The 2026 AACR Meeting - Yahoo Finance
Goldentree Asset Management LP Takes $149.60 Million Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals plc Denmark Finland France Germany Netherlands Sweden United Kingdom Ireland - AD HOC NEWS
JAZZ stock rises as Q4 earnings & sales top expectations - MSN
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting - Yahoo Finance
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 - PR Newswire
Faithward Advisors LLC Increases Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Aug Swings: Can Jazz Pharmaceuticals plc ride the EV wave2026 Major Catalysts & Expert-Curated Trade Recommendations - baoquankhu1.vn
Fundamentals Check: Can Jazz Pharmaceuticals plc ride the EV waveDip Buying & High Conviction Buy Zone Picks - baoquankhu1.vn
Holocene Advisors LP Acquires 135,367 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Ameriprise Financial Inc. Cuts Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Buybacks Report: Can Jazz Pharmaceuticals plc expand its profit margins2026 PostEarnings & Growth Oriented Trade Recommendations - baoquankhu1.vn
Iron Triangle Partners LP Makes New $19.77 Million Investment in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Aristotle Capital Management LLC - MarketBeat
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead? - TradingView
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Bank of Montreal Can - MarketBeat
Jazz Pharmaceuticals (JAZZ) Price Forecast: Multi-Year Base Signals Breakout Potential - FXEmpire
Jazz Pharmaceuticals at Barclays Conference: Strategic Growth Insights By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals at Barclays Conference: Strategic Growth Insights - Investing.com Nigeria
Capital World Investors Increases Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Crossmark Global Holdings Inc. Sells 10,433 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Revenue And Supportive Barclays Commentary - simplywall.st
Jazz Pharmaceuticals Stock at $185: Here’s Why Analysts See a New All-Time High in 2026 - TIKR.com
Jazz’s 2025 Net Loss and 2026 Outlook Might Change The Case For Investing In JAZZ - simplywall.st
Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Sells $235,443.78 in Stock - MarketBeat
Tax-withholding share disposition by Jazz Pharmaceuticals (JAZZ) director - Stock Titan
Jazz Pharmaceuticals (JAZZ) CFO reports tax-withholding share disposition - Stock Titan
Jazz Pharmaceuticals (JAZZ) EVP has 2,503 shares withheld to cover RSU taxes - Stock Titan
Jazz Pharmaceuticals (JAZZ) SVP Patricia Carr reports share sales - Stock Titan
Jazz Pharmaceuticals (JAZZ) CEO has shares withheld to cover RSU taxes - Stock Titan
Barclays reiterates Jazz Pharmaceuticals stock rating on CNS strength - Investing.com Nigeria
Patricia Carr (NASDAQ: JAZZ) files Form 144 showing recent share sales - Stock Titan
JAZZ or ACAD: Which Is the Better Value Stock Right Now? - Yahoo Finance
S&P 500 Futures Fall in Premarket Trading; Jazz Pharmaceuticals, Live Nation Ent Lead - Barron's
American Century Companies Inc. Sells 36,599 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):